Sight Sciences Initiates U.S. Pivotal Trial of the TearCare® System for the Treatment of Dry Eye Disease

APRIL 30, 2018

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced the initiation of the OLYMPIA study, a pivotal trial to evaluate the safety and effectiveness of the TearCare® System in patients with dry eye disease. The TearCare® System is the 
+ Read More


Sight Sciences Names Jesse Selnick Chief Financial Officer

MARCH 14, 2018

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced the appointment of Jesse Selnick as Chief Financial Officer. Selnick most recently served as Chief Financial Officer and on the Board of Directors of Electric Lightwave, a private equity sponsored 
+ Read More


Sight Sciences Expands Surgical Portfolio with FDA Clearance of the OMNI™ Surgical System

JANUARY 04, 2018

Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic device company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its OMNI™ Surgical System, a surgical tool dually indicated for the delivery of controlled volumes of viscoelastic fluid as well as the cutting of trabecular meshwork tissue. In addition, the company announced three key 
+ Read More


Sight Sciences Secures $10MM in Oversubscribed Series C Financing

OCTOBER 09, 2017

Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company today announced it has closed an oversubscribed $10 million Series C round of growth financing and strengthened its leadership team with a seasoned ophthalmic industry veteran. Allegro Investment Fund, a privately held fund based in Menlo Park, CA, led the round with full participation 
+ Read More


Sight Sciences Announces Health Canada Approval of the VISCO™360 Viscosurgical System for Standalone Microinvasive Glaucoma Surgery (MIGS)

APRIL 16, 2017

Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced today that it has received Health Canada approval for the VISCO™360 Viscosurgical System. The VISCO360 System is indicated in Canada for the microcatheterization and transluminal viscodilation of Schlemm’s canal to reduce intraocular pressure (IOP) in adult patients with open-angle glaucoma.* Performed as a standalone MIGS 
+ Read More


Sight Sciences Announces Expanding Management Team of Seasoned Medical Device Experts

FEBRUARY 15, 2017

Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced an expansion of its management team to support its recent regulatory milestones and commercial success. New hires include Anne-Marie Ripley, Vice President of Clinical and Regulatory Affairs, Ingrid Kane, M.D., Vice President of Global Medical Affairs, Jamie Chakales, Vice President of Global Sales 
+ Read More


Sight Sciences Announces Health Canada Approval of the TRAB™360 Trabeculotomy System

DECEMBER 23, 2016

Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received Health Canada approval for the TRAB™360 Trabeculotomy System. The TRAB™360 is indicated in Canada for the microcatheterization of Schlemm’s canal and cutting of trabecular meshwork to lower intraocular pressure (IOP) in patients with primary open angle glaucoma. From a 
+ Read More


Sight Sciences Announces CE Mark Approval for and Successful Commercial Experiences with the VISCO™360 Viscosurgical System for the Surgical Treatment of Glaucoma

OCTOBER 05, 2016

Sight Sciences, Inc., a venture backed, commercial stage ophthalmic medical device company announced today that the initial European commercial cases with the CE mark approved VISCO™360 Viscosurgical System will be presented Monday morning, September 12th during the European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Copenhagen, Denmark. The Glaucoma II Session will be 
+ Read More



Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO™360 Versus SLT Glaucoma Trial

JULY 26, 2016

Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world’s first clinical trial comparing ab interno canaloplasty with Selective Laser Trabeculoplasty (SLT). The VISCO™360 versus SLT Glaucoma Trial is a multi-center, prospective, randomized, controlled clinical evaluation that will study 
+ Read More